A detailed history of Octagon Capital Advisors LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 273,289 shares of IMVT stock, worth $7.21 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares
273,289
Previous 273,289 -0.0%
Holding current value
$7.21 Million
Previous $11.5 Million 23.31%
% of portfolio
1.38%
Previous 1.92%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $8.56 Million - $12.1 Million
273,289 New
273,289 $11.5 Million
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $3.03 Million - $5.06 Million
-895,939 Reduced 60.74%
579,061 $2.26 Million
Q1 2022

May 16, 2022

BUY
$5.06 - $8.77 $4.56 Million - $7.91 Million
902,138 Added 157.48%
1,475,000 $8.13 Million
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $4.2 Million - $5.34 Million
572,862 New
572,862 $4.88 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.41B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.